16-GI-100-NP (PDR001) An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Advanced or Metastatic Non-Functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin, Who Have Progressed